Another New Med In The Pipeline | Arthritis Information

Pfizer Inc. (NYSE:PFE) announced that the ORAL Sync Phase 3 study (A3921046) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis (RA), met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4(ESR) <2.6 at six months. The safety profile of tofacitinib was consistent with that seen previously in the clinical program, and no new safety signal was detected. A full analysis of efficacy and safety data will be submitted to a future scientific meeting.

About ORAL Sync

ORAL Sync evaluated the efficacy and safety of tofacitinib doses 5 mg and 10 mg given twice daily compared to placebo in patients with moderately to severely active RA who had a previous inadequate response to a DMARD and who continued to receive background traditional DMARD therapy throughout the study.

http://www.medicalnewstoday.com/articles/218304.phphhronbn562011-03-09 16:47:38hhronbn562011-03-09 16:43:59

What A Nasty Virus He Is

Hey ronbn56,

When that stroke hits ya, we'll see how much you hate the drug manufacturers. It's just a shame that people like you can still get the benifits of the drugs you call killers when you need them to save your worthless lives.

LEV